KCAS Bio

KCAS Bio is a top-tier contract research organization (CRO) that has 45 years of experience with both large pharma and biotech sponsors, providing comprehensive bioanalytical drug development services from early discovery through registration. We have supported more than 300+ FDA approved drugs on the market, developed 5,000+ proprietary and non-proprietary assays to date, and undergone 18 FDA audits with no major findings. Our presence in multiple locations throughout the US and Europe – and with a strategic alliance in Australia – allows us to serve sponsors globally with bioanalytical, biomarker, immunogenicity, cellular and molecular assay services along with clinical kitting and sample management. With the expertise, capacity and flexibility sponsors require, we can fulfill our purpose, which is to help accelerate the discovery and development of life-changing drugs smoothly, safely and sustainably.
International Society for Advancement of Cytometry (ISAC) – CYTO Annual Meeting
Identifying your CRO partner for flow cytometry services
KCAS Bioanalytical and Biomarker Services appoints John Bucksath as new CEO
A Spotlight on immunogenicity: an interview with Joyce Slusser
Immunogenicity assay development
Emerging immuno-oncology therapies
Panel Discussion: Hot Topics in Large Molecule Bioanalysis
Franklin Spriggs: validating bioanalytical methods for biomarkers
Immunogenicity services and capabilities at KCAS Bioanalytical & Biomarker Services
Development & Validation of a Direct Method for Quantification of DNA in Digested Tissue Samples
John Bucksath (KCAS Bioanalytical & Biomarker Services) on ‘one stop shop’ laboratory services
Panel discussion: new technology integration in bioanalytical workflows
John Bucksath (KCAS Bioanalytical & Biomarker Services) on ‘one stop shop’ laboratory services
Panel discussion: the sharing of scientific data
Why flow cytometry at KCAS? Solving the mysteries of flow cytometry
Panel discussion: bioanalytical considerations for oligonucleotide assessment strategies
Biomarker assay development: qualification vs validation debate
Panel discussion: evolving best practices in high-complexity flow cytometry
Bioanalytical considerations for immunogenicity of cell and gene therapies
Panel discussion: LBA and LC–MS/MS hybrid assays
Evolving best practices: considerations for conventional and spectral flow
Panel discussion: novel techniques and the new age of biomarkers
Panel discussion: gender parity in bioanalysis
Panel discussion: ICH M10 draft bioanalytical method validation guideline
Panel discussion: the evolution of flow cytometry
Panel discussion: strategies and challenges of immunogenicity
Panel discussion: what does the future hold for biomarker R&D?
Strategy for the selection and validation of your biomarkers for support of drug development
KCAS Bio specializes in the following services:
Bioanalysis
- Pharmacokinetics/ Toxicokinetics:
- LC-MS/MS, Hybrid LC-MS/MS, LBA, qPCR, ddPCR
- LNPs:
- LC-MS/MS, Hybrid LC-MS/MS
- Receptor occupancy:
- Flow cytometry
- Immunogenicity/ADA:
- LBA
- Biodistribution:
- qPCR, ddPCR
- Neutralizing antibodies assays:
- Cell-based, plate based
- Dose formulation analysis
- SEC, UPLC
Pharmacodynamics
- Primary endpoints
- Functional assays
- Secondary endpoints/ exploratory assays
Biomarkers
- Soluble biomarkers:
- LBA, qPCR, ddPCR, LC-MS/MS, MSD
- Cellular biomarkers:
- ELISpot, flow cytometry, qPCR, ddPCR, single-cell proteomics
Support
- Formulation analysis
- Sample kits (clinical/non clinical)
- Bio-repository
Learn more at www.kcasbio.com or follow us on twitter @KCASBio
Website:
www.kcasbio.com
Email:
[email protected]
Telephone:
913-248-3000
Address:
10830 S Clay Blair Blvd
Olathe, Kansas
66061
USA